Sharma Sheela, Gao Pu, Steele Vernon E
Cellular and Molecular Toxicology Program, Alion Life & Environmental Sciences, Research Triangle Park, NC 27709, USA.
Carcinogenesis. 2006 Aug;27(8):1721-7. doi: 10.1093/carcin/bgl052. Epub 2006 Apr 22.
This study explored the efficacy of oltipraz, a dithiolthione to prevent lung cancer by delivering it directly to the lung as inhaled particulates to obtain maximum efficacy with no toxicity. Two exposure regimens were used to compare the efficacies of early (Regimen-A) versus late (Regimen-B) intervention in prevention of lung tumorigenesis in A/J mice. Female A/J mice were exposed to 10, 30 and 100 mg/m(3) exposure concentrations of oltipraz for 1.0 h a day for 5 days per week for 4 weeks in Regimen A. During the second and third week, mice received totally 6 mg of B[a]P via gavage and after 16 weeks, they were killed for tumor counting and pathology. In Regimen B, mice were treated first with B[a]P and, after a gap of 4 weeks, exposed to oltipraz at 100 mg/m(3) for 16 additional weeks. At 22 weeks, animals were killed and necropsied for tumor scoring. The spontaneous tumors were few in untreated A/J mice (0.7 tumors/lung), whereas there was an average of 16.5 tumors per lung in the B[a]P group (20-fold induction). Evaluation of lung tumor multiplicity following exposure to oltipraz showed that oltipraz inhibited the tumor development in a dose-dependent manner (10-100 mg/m(3)) with inhibition ranging from 37 to 53% in Regimen A and 51% in Regimen B, when compared with the B[a]P group. Analysis of the tumor incidence showed that 81.5% of the animals had 10 or more tumors in the B[a]P group, whereas, in oltipraz exposure groups, there was a significant decrease in Regimen A (24-36%) and in Regimen B (42%). The data from this study show that oltipraz is an effective agent for lung cancer prevention, when it is delivered directly to the target tissue as aerosolized particulates.
本研究探讨了oltipraz(一种二硫代硫酮)作为吸入性颗粒直接递送至肺部以预防肺癌的疗效,旨在在无毒性的情况下获得最大疗效。采用两种暴露方案比较早期干预(方案A)与晚期干预(方案B)在预防A/J小鼠肺部肿瘤发生方面的疗效。在方案A中,雌性A/J小鼠每天暴露于浓度为10、30和100mg/m³的oltipraz中,每天暴露1.0小时,每周暴露5天,持续4周。在第二周和第三周,小鼠通过灌胃总共接受6mg的苯并[a]芘,16周后,将它们处死以进行肿瘤计数和病理学检查。在方案B中,小鼠首先用苯并[a]芘处理,间隔4周后,再暴露于浓度为100mg/m³的oltipraz中,持续16周。在22周时,处死动物并进行尸检以进行肿瘤评分。未处理的A/J小鼠自发肿瘤很少(每只肺0.7个肿瘤),而苯并[a]芘组平均每只肺有16.5个肿瘤(诱导了20倍)。暴露于oltipraz后对肺部肿瘤多样性的评估表明,oltipraz以剂量依赖性方式(10 - 100mg/m³)抑制肿瘤发展,与苯并[a]芘组相比,方案A中的抑制率为37%至53%,方案B中的抑制率为51%。对肿瘤发生率的分析表明,苯并[a]芘组中81.5%的动物有10个或更多肿瘤,而在oltipraz暴露组中,方案A(24% - 36%)和方案B(42%)有显著下降。本研究数据表明,当oltipraz作为雾化颗粒直接递送至靶组织时,它是一种有效的肺癌预防药物。